Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday each set estimated worth ranges of their preliminary public choices in an indication that the normal summer season lull in offers is coming to an finish.
Zenas BioPharma, Bicara Therapeutics units IPO worth ranges as summer season lull ends
